Pelvic Exenteration as the Treatment for Recurrent or Locally Advanced Rectal Cancer.
- Author:
Seong Kyu SONG
1
;
Yong Keun PARK
;
Kwang Wook SUH
Author Information
1. Department of Surgery, Ajou University School of Medicine, Suwon, Korea. suhkw@ajou.ac.kr
- Publication Type:Original Article
- Keywords:
Locally advanced rectal cancer;
Recurrent rectal cancer;
Pelvic exenteration
- MeSH:
Fistula;
Hemostasis;
Humans;
Medical Records;
Mortality;
Pelvic Exenteration*;
Postoperative Complications;
Rectal Neoplasms*;
Reoperation;
Retrospective Studies;
Survival Rate;
Wound Infection;
Wounds and Injuries
- From:Journal of the Korean Society of Coloproctology
2005;21(5):314-319
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The purpose of this study is to evaluate the value of pelvic exenteration (PE) for recurrent or locally advanced rectal cancer. METHODS: This retrospective study analyzed 20 patients who underwent PE for rectal cancer from June 1994 to October 2003 in Ajou University Hospital. The surgical severity, the postoperative complications, and the survival rate were analyed based on the medical records. RESULTS: The mean operation time was 221.5+/-93.0 minutes, the mean blood loss 750.5+/-223.3 cc, and the mean transfusion amount RBC 6.5+/-4.3 units. Operative mortality was 5% (1/20). A bleeding-associated complication was noted in one patient who underwent a reoperation for hemostasis. Other minor complications were small bowel obstruction (n=3), abdominal wound infection (n=5), vesicocutaneous fistula (n=2), delayed healing of the perineal wound (n=10). The overall 5-year survival rate was 52.6% (10 of 19 patients, excluding the operative mortality case). CONCLUSIONS: Our study showed acceptable surgical severity and postoperative complications and a favorable 5-year survival rate (> or =50%) for pelvic exenteration as a treatment for recurrent or locally advanced rectal cancer. With strictly selected patients, PE may be one of the treatment options for recurrent or locally advanced rectal cancer.
